RankingsPricing
  1. US-listed companies
  2. Citius Pharmaceuticals, Inc.
  3. Raw

Citius Pharmaceuticals, Inc.CTXR

Market cap
$10.7M
P/E ratio
SummaryFinancials
Back to summarized table
Sep 30,
2011		Sep 30,
2012		Sep 30,
2013		Sep 30,
2015		Sep 30,
2016		Sep 30,
2017		Sep 30,
2018		Sep 30,
2019		Sep 30,
2020		Sep 30,
2021		Sep 30,
2022		Sep 30,
2023		Sep 30,
2024
Revenues-------------
Research and development---23379912181512
General and administrative12,18716,24619,139946,6134666810121518
Stock-based compensation – general and administrative---486,271732,151986,620779,701715,983803,26114712
Total Operating Expenses41,13760,75588,873371014161824333742
Operating Loss-25,637-19,618-28,118-3,229,929-7,449,291-9,986,311-13,789,143-15,598,361-17,710,685-23,531,894-33,316,045-36,732,018-41,995,681
Interest income, net-------52,66068,066261,825251,3991758,000
Gain on sale of New Jersey net operating losses------450,000--166,557--2
Total Other Income Net-704--327,661-846,407-398,642136,217162,600477,460-53
Loss before Income Taxes----2,902,268-8,295,698-10,384,953-12,536,63816-17,548,085--33,064,646-31,966,912-38,849,839
Income tax expense----------576,000576,000576,000
Net Loss-------------39,425,839
Net loss attributable to non-controlling interest-------------287,000
Deemed dividend on warrant extension-----------11
Net Loss Applicable to Common Stockholders----------24,505,310-33,640,646-33,694,120-40,186,151
Net Loss Per Share Applicable to Common Stockholders - Basic (in Dollars per share)-----------0.23--5.97
Net Loss Per Share Applicable to Common Stockholders - Diluted (in Dollars per share)-----------0.23--5.97